Is dapagliflozin beneficial in a patient with chronic kidney disease stage 3a (estimated glomerular filtration rate 45–59 mL/min/1.73 m²)?

Dapagliflozin is Highly Beneficial in CKD Stage 3a

Yes, dapagliflozin is strongly recommended for patients with CKD stage 3a (eGFR 45-59 mL/min/1.73 m²) and provides significant kidney and cardiovascular protection regardless of diabetes status. The 2022 ADA/KDIGO consensus guidelines explicitly recommend SGLT2 inhibitors with proven kidney or cardiovascular benefit for patients with CKD and eGFR ≥20 mL/min/1.73 m² 1.

Evidence for CKD Stage 3a

For patients with CKD stage 3a, dapagliflozin 10 mg daily is the appropriate dose with no adjustment needed 1, 2. The FDA label specifically states that dapagliflozin is approved for use at 10 mg once daily with eGFR ≥25 mL/min/1.73 m² for kidney protection indications 2.

The DERIVE study directly evaluated dapagliflozin in patients with type 2 diabetes and CKD stage 3a (eGFR 45-59 mL/min/1.73 m²), demonstrating significant reductions in HbA1c (-0.34%), body weight (-1.25 kg), and systolic blood pressure (-3.1 mmHg) compared to placebo over 24 weeks 3. Importantly, the initial eGFR decline reversed after stopping treatment, confirming the hemodynamic rather than harmful nature of the acute dip.

Kidney Protection Benefits

The landmark DAPA-CKD trial provides the strongest evidence: dapagliflozin reduced the composite of sustained eGFR decline ≥50%, end-stage kidney disease, or renal/cardiovascular death by 39% (HR 0.61,95% CI 0.51-0.72, p<0.001) in patients with CKD (eGFR 25-75 mL/min/1.73 m²) 4. This benefit occurred regardless of diabetes status - a critical point for CKD stage 3a patients without diabetes.

Mechanistically, dapagliflozin slows chronic eGFR decline by approximately 1 mL/min/1.73 m² per year compared to placebo 5. After an initial acute eGFR dip of 2-3 mL/min/1.73 m² in the first 2 weeks (which is hemodynamic and reversible), the chronic slope shows marked preservation of kidney function 1.

Cardiovascular Benefits

Beyond kidney protection, dapagliflozin reduces cardiovascular death or heart failure hospitalization by 29% (HR 0.71,95% CI 0.55-0.92) 4. The 2022 Canadian guidelines strongly recommend SGLT2 inhibitors for cardiorenal risk reduction in CKD patients with eGFR ≥25 mL/min/1.73 m² 6.

Practical Implementation for CKD Stage 3a

Initiation approach:

• Start dapagliflozin 10 mg once daily 1, 2
• No dose adjustment needed for eGFR 45-59 mL/min/1.73 m² 1
• Expect an acute eGFR dip of 2-3 mL/min/1.73 m² within 2 weeks - this is expected and beneficial 7, 1
• Continue therapy even if eGFR subsequently falls below 45 mL/min/1.73 m² 1

Monitoring strategy:

• Assess volume status before initiation; correct hypovolemia first 1
• Monitor eGFR at 2-4 weeks, then every 3-6 months 8
• Reduce diuretic doses in patients at risk for volume depletion 7
• If on insulin or sulfonylureas, reduce doses to prevent hypoglycemia (though glucose-lowering effect is modest at this eGFR) 1

Safety Considerations

The safety profile in CKD stage 3a is well-established 2, 3:

• Genital mycotic infections: Occur in ~6% (vs 1% placebo); counsel on hygiene 1
• Volume depletion: Risk is low; consider diuretic reduction in high-risk patients 7
• Diabetic ketoacidosis: Rare; implement sick-day rules (hold during acute illness) 1, 7
• Hypoglycemia: Only if combined with insulin/secretagogues; adjust those medications 1

Critical pitfall to avoid: Do not discontinue dapagliflozin due to the initial eGFR dip. The DAPA-CKD protocol specifically continued treatment when eGFR fell below initiation thresholds, and this approach maximizes long-term kidney protection 1.

Albuminuria Considerations

While the strongest trial evidence comes from patients with UACR ≥200 mg/g 4, recent real-world data demonstrates kidney protection across all albuminuria levels, including normal/mildly elevated albuminuria 9. The 2025 KDOQI commentary notes that eGFR slope analyses support benefit even in patients with UACR <200 mg/g 7.

For CKD stage 3a patients:

• With UACR ≥200 mg/g: Strong recommendation (1A evidence) 7
• With UACR 30-200 mg/g: Recommended based on consistent mechanistic benefit 7
• With UACR <30 mg/g: Consider initiation, particularly if cardiovascular risk factors present 7

Bottom Line Algorithm

Initiate dapagliflozin 10 mg daily in CKD stage 3a if:

1. eGFR 45-59 mL/min/1.73 m² (confirmed)
2. No active dialysis requirement
3. Patient is euvolemic or volume status corrected
4. Not acutely ill or scheduled for major surgery within 3 days 2

Continue indefinitely - even if eGFR declines below 45 or 25 mL/min/1.73 m² during treatment 1, 2. Only discontinue if dialysis is initiated or intolerable side effects occur.

The evidence overwhelmingly supports dapagliflozin use in CKD stage 3a for reducing kidney disease progression, cardiovascular events, and mortality 1, 4.